Roche shares surge as a double-shot win in I/O and hemophilia raises blockbuster expectations
Roche has scored a win with one of the key immuno/oncology trials of the year, posting significant top-line gains for progression-free survival and risk of death for a segment of lung cancer patients getting first-line treatment with a triple combo of its checkpoint therapy Tecentriq, Avastin and chemo. And it swept a double header early this morning with their report of another successful late-stage study for its newly approved hemophilia A drug Hemlibra, further setting the stage for a painful showdown with market leader Shire.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
